SCYNEXIS names Steven K. Burke to board as ADPKD program advances
The clinical-stage biotech added a kidney disease drug development veteran to its board as it works toward a Phase 2 study of SCY-770.
SEC filing
Latest
2 stories
Tuesday, September 22
Wednesday, August 5
Akebia reports Q2 2026 results, VOICE interim data, and new ebribafusp trial
Vafseo revenue rose to $21.3 million as Akebia started a Phase 2 basket trial in three rare kidney diseases and cited positive interim safety data from the VOICE trial.
SEC filing